CMS’s CGT Access Model now covers Casgevy and Lyfgenia for sickle cell through 33 state Medicaid programs under outcomes-based contracts. Here’s what patients need to know.
Medicaid Will Cover Sickle Cell Gene Therapy, but Only When It Actually Works for the Patient
by | Jul 8, 2026 | Uncategorized | 0 comments
Recent Comments